Learn about Surgiwear Limited’s Draft Red Herring Prospectus filing, business operations, financial context, and the proposed utilisation of funds as outlined in public disclosures.
Surgiwear Limited has filed its Draft Red Herring Prospectus (DRHP) with the Securities and Exchange Board of India (SEBI) as part of its plan to raise capital through an initial public offering. The DRHP outlines the company’s business profile, operational strengths, financial disclosures, and the broad structure of the proposed public issue.
The DRHP provides an overview of the proposed IPO and sets out the company’s financials, governance framework, and business outlook.
Surgiwear Limited has submitted its Draft Red Herring Prospectus to SEBI in January 2026, marking the formal initiation of its IPO process. The filing is currently under regulatory review, following which SEBI observations and approvals will determine the next stages, including the filing of the Red Herring Prospectus (RHP) and announcement of issue dates. The equity shares are proposed to be listed on recognised stock exchanges in India, subject to regulatory clearances.
As per the DRHP, the proposed IPO is expected to comprise the following components:
| Particulars | Details |
|---|---|
Issue Type |
Fresh Issue of Equity Shares and Offer for Sale (OFS) |
Face Value |
To be disclosed in RHP |
Issue Size |
To be determined based on final price band |
Proposed Listing |
NSE and BSE |
Price Band |
To be announced in RHP |
Offer Structure |
Fresh Issue + Offer for Sale by existing shareholders |
These details reflect indicative disclosures available at the DRHP stage and are subject to change based on SEBI observations and final approvals.
Surgiwear Limited operates in the medical devices and surgical products segment, with a focus on the manufacturing of surgical instruments, orthopedic implants, and related medical devices. The company supplies products to hospitals, surgical centres, healthcare providers, and distributors across India and international markets.
Its manufacturing operations are supported by advanced production technology, precision manufacturing systems, and quality assurance infrastructure that meets medical device manufacturing standards. Surgiwear Limited’s product portfolio includes forceps, scissors, retractors, specialised surgical tools, and orthopedic implants used in diverse surgical procedures.
The company’s business model is centred on manufacturing excellence, regulatory compliance, product quality, and long-standing relationships with healthcare providers. Its market presence is supported by rising surgical procedures, expanding healthcare infrastructure, and increasing demand for high-quality surgical and orthopedic devices in India.
According to the DRHP, the proceeds from the fresh issue are proposed to be utilised towards the following broad objectives:
| Fund Allocation | Purpose |
|---|---|
Capital Expenditure |
Expansion of manufacturing facilities, advanced surgical instrument and orthopedic implant production equipment, precision manufacturing infrastructure, and quality testing laboratories |
Debt Repayment |
Partial repayment of borrowings to optimise capital structure |
General Corporate Purposes |
Administrative and strategic operational requirements |
The offer for sale component will provide liquidity to existing shareholders, enabling partial exits while maintaining management continuity.
The DRHP provides an overview of Surgiwear Limited’s financial performance over recent periods. Detailed audited figures are available in the prospectus.
| Fiscal Year / Period | Revenue (₹ in Crore) | EBITDA (₹ in Crore) | Profit After Tax (PAT) (₹ in Crore) |
|---|---|---|---|
FY24 |
168.74 |
54.72 |
22.50 |
FY25 |
223.98 |
98.98 |
57.95 |
H1 FY26 |
44.61 |
~14.29 |
5.61 |
*Detailed year-wise financial statements, including audited figures, are available in the DRHP and should be referred to for complete financial information.
The table below summarises the current status of the IPO process based on publicly available information:
| Milestone / Stage | Date (or Status) | Details |
|---|---|---|
DRHP filed with SEBI |
January 2026 |
Draft Red Herring Prospectus submitted for regulatory review |
SEBI observations |
Awaited |
Subject to regulatory review |
SEBI approval |
Awaited |
Approval valid for 12 months from grant |
Red Herring Prospectus (RHP) |
To be announced |
Post SEBI approval |
IPO Opening Date |
To be announced |
Final dates awaited |
IPO Closing Date |
To be announced |
As per official RHP |
Allotment Date |
To be announced |
Post IPO closure |
Credit to DEMAT Accounts |
To be announced |
Post allotment |
Listing on NSE/BSE |
To be announced |
Subject to completion of listing formalities |
Note: Investors should refer to official filings for final IPO dates to learn more about Surgiwear Limited IPO listing details and price, and listing timelines.
Keep yourself updated : Check Upcoming IPO
This content is for informational purposes only and the same should not be construed as investment advice. Bajaj Finserv Direct Limited shall not be liable or responsible for any investment decision that you may take based on this content.
Sources
LiveMint — IPO News and Updates, https://www.livemint.com/market/ipo
Economic Times — IPO News: Latest IPO News, Upcoming IPO, https://economictimes.indiatimes.com/markets/ipo
Financial Express — IPO News, https://www.financialexpress.com/market/ipo-news/
NDTV Profit — IPOs, https://www.ndtvprofit.com/ipos
Business Today — IPO Corner: Latest IPO News & Analysis, https://www.businesstoday.in/markets/ipo-corner
Surgiwear Limited filed its Draft Red Herring Prospectus with the Securities and Exchange Board of India on 7 January 2026, marking the formal start of its IPO process for a book-built issue of up to ₹740 Crores.
The Surgiwear Limited IPO is currently at the Draft Red Herring Prospectus review stage, with SEBI observations and approval awaited before finalising the Red Herring Prospectus and announcing the subscription dates.
The Surgiwear Limited IPO comprises a fresh issue of equity shares worth ₹370 Crores along with an offer for sale of ₹370 Crores by existing shareholders, with final size determined after price band announcement.
Subject to regulatory approvals, Surgiwear Limited proposes to list its equity shares on both the National Stock Exchange and the Bombay Stock Exchange for secondary market trading post-allotment.
Proceeds from Surgiwear Limited's fresh issue are proposed for capital expenditure on manufacturing facility machinery, prepayment or repayment of outstanding borrowings, and general corporate purposes to support business expansion.